The rights to key patents for an innovative screening tool for treatments for cystic fibrosis were transferred to Swiss biotech company Axentis Pharma AG. The company has acquired the rights from an Austrian firm that has made a vital contribution to the development of new approaches to treating the disease.
The core element of the platform technology involves human proteins which despite offering sufficient functionality are subjected to enzymatic digestion in untreated cells due to genetic mutations in their structure.
The details can be read here.
No comments:
Post a Comment